New Delhi: Council of Scientific and Industrial Research (CSIR) and Lakshai Life Sciences Pvt. Ltd. has been given regulatory approval by the DCGI for a Face-2 clinical trial to assess the safety and efficacy of the colcicin (Colchicine) drug to improve clinical results during the treatment of covid patients.
The major clinical trials include CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad and CSIR-Indian Institute of Integrated Medicine (IIIM), Jammu among the partners in the CSIR Institutes. Dr. Shekhar C. Mande, Director General, CSIR has said that the cosicin drug will be an important medical intervention to reduce covid patients and proinflammatory cytokines with cardiac co-morphidites, leading to faster recovery.
Several international studies have confirmed that many patients have died of cardiovascular complications during corona infection and post-covid syndrome, and it has become necessary to look for new or renovated drugs. Two associate institutions in the CSIR said they are waiting for the results of this second phase of clinical efficacy trial on colcicin, which can save the lives of admitted patients in the hospital.
IMD issues Orange alert for six districts in MP as monsoon set to advance
Riz Ahmed slams Hollywood for 'toxic' portrayal of Muslims and 'frankly racist' movies
